(P007) Cardiac and Left Anterior Descending Artery Sparing for Left Whole-Breast Radiation Therapy in the Prone vs Supine Free Breathing and Deep Inspiration Breath-Hold Positioning: A Single-Institution Experience

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

Equal heart sparing can be achieved in left WBRT in either the prone or supine position with deep inspiration breath hold or free breathing when planning is individualized and driven by appropriate dose constraints.

Ashley Sekhon, MD, Dominic DiCostanzo, Karla Kuhn, Julia White, MD; Ohio State University

OBJECTIVE: The UK HeartSpare Study (stage IB) suggested that left whole-breast radiation therapy (WBRT) using a deep inspiration breath-hold (DIBH) technique provided superior heart and left anterior descending artery (LAD) sparing as compared with treatment in the prone position. In this retrospective investigation, we sought to confirm that individualized care based on a patient’s anatomy and predefined dosimetric constraints can result in equivalent cardiac sparing.

METHODS: Women diagnosed with early-stage invasive carcinoma or ductal carcinoma in situ (DCIS) of the left breast who received WBRT using supine positioning with the DIBH or free-breathing (FB) technique, vs prone positioning, between January 2014 and August 2015 were studied. A total of 20 left-sided supine cases were identified: 10 FB and 10 with DIBH. The last consecutive 20 left-sided prone cases treated prior to August 2015 were studied. The following cardiac constraints were utilized: mean heart dose < 4 Gy, V (≥ 25 Gy) < 5% , and max heart dose < 45 Gy. The LAD was contoured retrospectively on each planning CT scan. Mean doses delivered to the heart and LAD were extracted from the planning software. Patient body mass index (BMI) and breast planning target volumes (PTVs) were also recorded. Parameters were compared using the unpaired t-test.

RESULTS: Prescribed whole-breast doses ranged from 42.56–50 Gy; 75% of cases received a lumpectomy cavity boost of 10–14 Gy. Mean heart and LAD doses (Gy) for DIBH and prone treatments were 1.24 vs 1.05 (P = .17) and 7.57 vs 5.50 (P = .42), respectively. There was no statistically significant difference in these parameters when prone was compared with FB or when DIBH was compared with FB. Mean BMI and breast PTVs were similar between all groups.

CONCLUSION: Equal heart sparing can be achieved in left WBRT in either the prone or supine position with DIBH or FB when planning is individualized and driven by appropriate dose constraints.

Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Related Content